FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1396076> ?p ?o ?g. }

• W1396076 endingPage "13" @default.
• W1396076 startingPage "303" @default.
• W1396076 abstract "The effect of temperature stresses on Cefaclor suspensions under different storage conditions for a duration of 14 days was tested. The degradation of Cefaclor was determined on the 2nd, 7th and 14th day after reconstitution using a sensitive and precise Reversed phase High Performance Liquid Chromatographic (RP-HPLC) method. The RSD values for Forticef, Midocef, Ceclor, Cefabac and Cloracef, indicated a good precision of the RP-HPLC method. The limit of detection (LOD) and the limit of quantification (LOQ) were found 0.008 mg/ml and 0.03mg/ml respectively. The antimicrobial effect of Cefaclor suspension was also tested against pathogenic bacteria using the cylinder diffusion method. The RSD values range of the antimicrobial assay for all the Cefaclor compounds were 1.47-3.7%. The LOD and LOQ were 0.2mg/ml and 1mg/ml respectively. During the normal use of Ceclor, Midocef, and Forticef the loss of activity and the degradation were less than 5% on the 14th day of preservation at 4°C. However, the percentage of degradation for Cefabac and Cloracef on the 14th day reached 5 and 6%, respectively. Statistical multiple comparison between the effect of 4°C and 25°C indicated non significant mean differences (P>0.05) for Forticef, Cefabac, Ceclor and Cloraf and significant effect for Midocef (P <0.05). Significant effects were observed between (4oC and 37°C) and (25°C and 37°C) for all except Ceclor. Multiple comparisons between days of storage showed non significant mean difference values at 4°C except Cefabac. However significant results between days were found at 25°C and 37°C except for Midocef between (7th and 14th day). It was found that the pediatric suspensions of Cefaclor in the Jordanian market were stable and contained the amount of active ingredient specified by the United States pharmacopoeias specification (USP) and the British Pharmacopoeias specifications (BP)." @default.
• W1396076 created "2016-06-24" @default.
• W1396076 creator A5026216623 @default.
• W1396076 creator A5029155484 @default.
• W1396076 creator A5055858808 @default.
• W1396076 creator A5066645774 @default.
• W1396076 creator A5075158048 @default.
• W1396076 creator A5081344848 @default.
• W1396076 date "2011-07-01" @default.
• W1396076 modified "2023-09-23" @default.
• W1396076 title "Evaluation of cefaclor oral suspensions stability using reversed phase high performance liquid chromatography and antimicrobial diffusion methods." @default.
• W1396076 cites W1973979849 @default.
• W1396076 cites W2026760500 @default.
• W1396076 cites W2040670775 @default.
• W1396076 cites W2047546584 @default.
• W1396076 cites W2083225711 @default.
• W1396076 cites W2111383313 @default.
• W1396076 cites W2121268096 @default.
• W1396076 cites W2125186635 @default.
• W1396076 cites W2145060925 @default.
• W1396076 cites W2166785990 @default.
• W1396076 cites W2269101275 @default.
• W1396076 cites W2314753360 @default.
• W1396076 cites W2911263711 @default.
• W1396076 cites W33831771 @default.
• W1396076 cites W575957362 @default.
• W1396076 cites W591980246 @default.
• W1396076 cites W61898644 @default.
• W1396076 cites W2520797214 @default.
• W1396076 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21715263" @default.
• W1396076 hasPublicationYear "2011" @default.
• W1396076 type Work @default.
• W1396076 sameAs 1396076 @default.
• W1396076 citedByCount "7" @default.
• W1396076 countsByYear W13960762019 @default.
• W1396076 countsByYear W13960762020 @default.
• W1396076 countsByYear W13960762022 @default.
• W1396076 crossrefType "journal-article" @default.
• W1396076 hasAuthorship W1396076A5026216623 @default.
• W1396076 hasAuthorship W1396076A5029155484 @default.
• W1396076 hasAuthorship W1396076A5055858808 @default.
• W1396076 hasAuthorship W1396076A5066645774 @default.
• W1396076 hasAuthorship W1396076A5075158048 @default.
• W1396076 hasAuthorship W1396076A5081344848 @default.
• W1396076 hasConcept C119128265 @default.
• W1396076 hasConcept C178790620 @default.
• W1396076 hasConcept C179998833 @default.
• W1396076 hasConcept C185592680 @default.
• W1396076 hasConcept C2779766023 @default.
• W1396076 hasConcept C2780131815 @default.
• W1396076 hasConcept C43617362 @default.
• W1396076 hasConcept C4937899 @default.
• W1396076 hasConcept C501593827 @default.
• W1396076 hasConcept C55493867 @default.
• W1396076 hasConcept C64778159 @default.
• W1396076 hasConceptScore W1396076C119128265 @default.
• W1396076 hasConceptScore W1396076C178790620 @default.
• W1396076 hasConceptScore W1396076C179998833 @default.
• W1396076 hasConceptScore W1396076C185592680 @default.
• W1396076 hasConceptScore W1396076C2779766023 @default.
• W1396076 hasConceptScore W1396076C2780131815 @default.
• W1396076 hasConceptScore W1396076C43617362 @default.
• W1396076 hasConceptScore W1396076C4937899 @default.
• W1396076 hasConceptScore W1396076C501593827 @default.
• W1396076 hasConceptScore W1396076C55493867 @default.
• W1396076 hasConceptScore W1396076C64778159 @default.
• W1396076 hasIssue "3" @default.
• W1396076 hasLocation W13960761 @default.
• W1396076 hasOpenAccess W1396076 @default.
• W1396076 hasPrimaryLocation W13960761 @default.
• W1396076 hasRelatedWork W1913148260 @default.
• W1396076 hasRelatedWork W1982761938 @default.
• W1396076 hasRelatedWork W2009196049 @default.
• W1396076 hasRelatedWork W2013299392 @default.
• W1396076 hasRelatedWork W2032191029 @default.
• W1396076 hasRelatedWork W2080191601 @default.
• W1396076 hasRelatedWork W2094053692 @default.
• W1396076 hasRelatedWork W3029450219 @default.
• W1396076 hasRelatedWork W3085245795 @default.
• W1396076 hasRelatedWork W2515808157 @default.
• W1396076 hasVolume "24" @default.
• W1396076 isParatext "false" @default.
• W1396076 isRetracted "false" @default.
• W1396076 magId "1396076" @default.
• W1396076 workType "article" @default.